Correction - Exercise of Warrants

Nuformix PLC

14 April 2025

 

14 April 2025

The following correction is being made to the "Exercise of Warrants" announcement released on 14 April 2025 at 07:00 under RNS No. 8610E.

In the "Exercise of Warrants" announcement released today at 07:00 it was stated that it is expected that Admission will become effective and dealings in the New Ordinary Shares will commence at 8.00 a.m. on 18 April 2025.  This should have stated that it is expected that Admission will become effective and dealings in the New Ordinary Shares will commence at 8.00 a.m. on 22 April 2025.

All other details remain unchanged.

The full text is shown below.

Nuformix plc

("Nuformix" or the "Company")

Exercise of Warrants

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that it has received a notice of exercise of broker warrants to subscribe for a total of 26,400,000 new ordinary shares of 0.05 pence each in the capital of the Company ("Ordinary Shares") (the "New Ordinary Shares"). The New Ordinary Shares are being issued at a price of 0.05 pence per share, for a total consideration to the Company of £13,200.

The New Ordinary Shares will rank pari passu with the existing Ordinary Shares and application has been made for the New Ordinary Shares to be admitted to the Official List of the FCA and to trading on the Main Market of the London Stock Exchange ("Admission").  It is expected that Admission will become effective and dealings in the New Ordinary Shares will commence at 8.00 a.m. on 22 April 2025.

Total Voting Rights

Upon Admission, the Company's issued share capital will consist of 1,695,709,368 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 1,695,709,368.  With effect from Admission, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
CMC Markets
Douglas Crippen	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

END